ERBB2 and breast cancer: Additionally, a study performed by Li et al. [284] confirmed that C3G treatment inhibited the overexpression of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor [285], induced apoptosis of trastuzumab-resistant breast cancer cells, and suppressed their migration and invasion.